IL140244A0 - Heterocyclic compounds as inhibitors of rotamase enzymes - Google Patents

Heterocyclic compounds as inhibitors of rotamase enzymes

Info

Publication number
IL140244A0
IL140244A0 IL14024499A IL14024499A IL140244A0 IL 140244 A0 IL140244 A0 IL 140244A0 IL 14024499 A IL14024499 A IL 14024499A IL 14024499 A IL14024499 A IL 14024499A IL 140244 A0 IL140244 A0 IL 140244A0
Authority
IL
Israel
Prior art keywords
inhibitors
heterocyclic compounds
rotamase enzymes
rotamase
enzymes
Prior art date
Application number
IL14024499A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL140244A0 publication Critical patent/IL140244A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14024499A 1998-07-21 1999-06-28 Heterocyclic compounds as inhibitors of rotamase enzymes IL140244A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles
PCT/IB1999/001211 WO2000005232A1 (en) 1998-07-21 1999-06-28 Heterocyclic compounds as inhibitors of rotamase enzymes

Publications (1)

Publication Number Publication Date
IL140244A0 true IL140244A0 (en) 2002-02-10

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14024499A IL140244A0 (en) 1998-07-21 1999-06-28 Heterocyclic compounds as inhibitors of rotamase enzymes

Country Status (45)

Country Link
US (2) US6372736B1 (id)
EP (1) EP1100797B1 (id)
JP (2) JP3795329B2 (id)
KR (2) KR100468185B1 (id)
CN (3) CN1611499A (id)
AP (1) AP2001002046A0 (id)
AR (1) AR019427A1 (id)
AT (1) ATE233261T1 (id)
AU (1) AU765925B2 (id)
BG (1) BG105254A (id)
BR (1) BR9912330A (id)
CA (1) CA2338214C (id)
CO (1) CO5080782A1 (id)
CR (1) CR6073A (id)
DE (1) DE69905582T2 (id)
DK (1) DK1100797T3 (id)
DZ (1) DZ2851A1 (id)
EA (1) EA003513B1 (id)
EE (1) EE200100044A (id)
ES (1) ES2191484T3 (id)
GB (1) GB9815880D0 (id)
GE (1) GEP20033028B (id)
GT (1) GT199900115A (id)
HK (1) HK1039779A1 (id)
HN (1) HN1999000106A (id)
HR (1) HRP20010052A2 (id)
HU (1) HUP0103413A3 (id)
ID (1) ID26991A (id)
IL (1) IL140244A0 (id)
IS (1) IS5790A (id)
MA (1) MA24936A1 (id)
MY (1) MY118222A (id)
NO (1) NO20010322L (id)
NZ (2) NZ522270A (id)
OA (1) OA11585A (id)
PA (1) PA8478501A1 (id)
PE (1) PE20001037A1 (id)
PL (1) PL345734A1 (id)
SI (1) SI1100797T1 (id)
SK (1) SK772001A3 (id)
SV (1) SV1999000102A (id)
TN (1) TNSN99147A1 (id)
TR (1) TR200100135T2 (id)
TW (1) TWI229672B (id)
WO (1) WO2000005232A1 (id)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
CA2349227C (en) 1998-11-03 2008-02-05 Basf Aktiengesellschaft Substituted 2-phenylbenzimidazoles, the production thereof and their use
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
DK1778637T3 (da) * 2004-06-29 2012-06-18 Aventis Pharma Inc FKBP-bindingssammensætninger og farmaceutisk anvendelse deraf
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
JP5227796B2 (ja) * 2005-09-29 2013-07-03 アボット・ラボラトリーズ 2位においてフェニルによって置換された1h−ベンズイミダゾール−4−カルボキサミドは強力なparp阻害薬である
ATE461923T1 (de) * 2005-11-15 2010-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
SI1976828T1 (sl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
WO2007131016A2 (en) * 2006-05-02 2007-11-15 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
MX2009006543A (es) * 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
AR065628A1 (es) * 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
JP2010535708A (ja) * 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
WO2015179414A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
EP3801559A4 (en) 2018-05-31 2022-03-02 Celltaxis, LLC METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
HUP0103413A3 (en) 2002-10-28
DK1100797T3 (da) 2003-04-22
CN1611499A (zh) 2005-05-04
AU765925B2 (en) 2003-10-02
KR20040062640A (ko) 2004-07-07
JP2002521382A (ja) 2002-07-16
MY118222A (en) 2004-09-30
EA200100052A1 (ru) 2001-06-25
PA8478501A1 (es) 2000-05-24
HUP0103413A2 (hu) 2002-05-29
SV1999000102A (es) 2000-07-06
KR100450008B1 (ko) 2004-09-24
AP2001002046A0 (en) 2001-03-31
EP1100797B1 (en) 2003-02-26
NZ508838A (en) 2002-12-20
EA003513B1 (ru) 2003-06-26
CA2338214C (en) 2006-08-01
IS5790A (is) 2000-12-22
SK772001A3 (en) 2001-12-03
GB9815880D0 (en) 1998-09-16
KR100468185B1 (ko) 2005-01-26
TNSN99147A1 (fr) 2005-11-10
AR019427A1 (es) 2002-02-20
KR20010071013A (ko) 2001-07-28
CO5080782A1 (es) 2001-09-25
BG105254A (en) 2001-10-31
HK1039779A1 (zh) 2002-05-10
PL345734A1 (en) 2002-01-02
DE69905582T2 (de) 2003-09-04
JP2004002374A (ja) 2004-01-08
NO20010322D0 (no) 2001-01-19
US6372736B1 (en) 2002-04-16
CN1174978C (zh) 2004-11-10
JP3795329B2 (ja) 2006-07-12
CA2338214A1 (en) 2000-02-03
BR9912330A (pt) 2001-04-17
US6562964B1 (en) 2003-05-13
HN1999000106A (es) 1999-11-11
EP1100797A1 (en) 2001-05-23
TR200100135T2 (tr) 2001-06-21
NO20010322L (no) 2001-03-15
ID26991A (id) 2001-02-22
HRP20010052A2 (en) 2001-12-31
ATE233261T1 (de) 2003-03-15
NZ522270A (en) 2004-03-26
EE200100044A (et) 2002-06-17
PE20001037A1 (es) 2000-10-11
MA24936A1 (fr) 2000-04-01
DZ2851A1 (fr) 2004-02-04
AU4285899A (en) 2000-02-14
OA11585A (en) 2004-07-26
WO2000005232A1 (en) 2000-02-03
GEP20033028B (en) 2003-07-25
CN1310718A (zh) 2001-08-29
GT199900115A (es) 2001-01-10
TWI229672B (en) 2005-03-21
ES2191484T3 (es) 2003-09-01
DE69905582D1 (de) 2003-04-03
SI1100797T1 (en) 2003-06-30
CR6073A (es) 2004-04-29
CN1511837A (zh) 2004-07-14

Similar Documents

Publication Publication Date Title
IL140244A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes
AU2181099A (en) Heterocyclic compounds as inhibitors of rotamase enzymes
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
PL344046A1 (en) Heterocyclic inhibitors of p38
EP1127054A4 (en) INHIBITORS OF IMPDH ENZYME
AU2002331311A1 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
IL135574A0 (en) Substituted 4-amino-thiazol-2-yl compounds as cdk inhibitors
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
PL350911A1 (en) Inhibitors of impdh enzyme
GB9800575D0 (en) Heterocyclic compounds
EP1001764A4 (en) Heterocyclic amides as cell adhesion inhibitors
AU8059598A (en) Heterocyclic amide compounds as cell adhesion inhibitors
IL137929A0 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU1817700A (en) 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
AP2002002413A0 (en) Heterocyclic compounds inhibiting angiogenesi
AU5999698A (en) Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
AU1176299A (en) Tryptase inhibitors comprising heterocyclic amide compounds
PL339287A1 (en) Method of obtaining heterocyclic compounds and novel intermediate compounds
GB9823420D0 (en) Process for making phenyl heterocylces useful as cox-2 inhibitors
GB9613110D0 (en) Process for making phenyl heterocyclic useful as cox-2 inhibitors
AU2825999A (en) Novel heterocyclic compounds
SI1109560T1 (en) Compounds useful as aicarft inhibitors
AU2714699A (en) Novel heterocyclic compounds
GB9812403D0 (en) Heterocyclic compounds